CARR Biosystems is a leading provider of advanced bioprocessing solutions, specializing in high-performance separation technologies that support the development and manufacturing of next-generation therapeutics. With decades of expertise in centrifugation, the company delivers scalable, low-shear systems designed to optimize the production of sensitive biological products, particularly within the advanced therapies sector.

In cell and gene therapy applications, CARR Biosystems enables efficient cell harvesting, washing, and media exchange while preserving cell viability and functionality. Its single-use UniFuge® platform minimizes contamination risk through closed-system processing and supports seamless scalability from early research through commercial manufacturing. These capabilities are critical for maintaining product integrity in complex workflows such as gene editing, viral vector production, and cell expansion.

The company’s technologies also enhance gene therapy manufacturing by improving viral vector recovery, reducing downstream impurities, and minimizing filtration requirements. By leveraging gentle tubular bowl centrifugation, CARR systems protect shear-sensitive materials while increasing yield and process efficiency.

CARR Biosystems helps biopharmaceutical developers speed up advanced therapy pipelines with reliable, automated, scalable solutions that deliver high recovery rates, consistent performance, and regulatory-ready manufacturing processes.